SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gilead Science (GILD) Followers
GILD 125.67+0.4%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brian Sullivan who wrote (939)4/11/2020 11:05:10 AM
From: zax   of 961
 
I suspect GILD will see a nice bump on Monday... courtesy the cover of today's Washington Post:

Gilead’s experimental drug remdesivir shows ‘hopeful’ signs in small group of coronavirus patients

Two-thirds of severely ill patients showed some improvement when treated with the antiviral medicine.A majority of a small group of patients showed improvements after being treated with an experimental coronavirus drug made by Gilead Sciences, bolstering hopes for finding a treatment for the disease, according to a study published in the New England Journal of Medicine on Friday.

The group of patients received the antiviral drug remdesivir as part of a “compassionate use'' trial, not a double-blind, placebo-controlled trial that would offer more definitive evidence. Also, the cohort of patients was small, only 53 patients in the United States and around the world. Those limiting factors prevent scientists from declaring that the drug works.

Still, the improvements offered positive news about a drug seen by global health authorities as offering the best shot at becoming a treatment for the disease.

Thirty-six patients out of 53 — or about two-thirds — showed improvement in oxygen support, trial authors said. Seventeen of 30 patients who were on ventilators were able to be taken off the life-support machines.

... washingtonpost.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News